I In nt tr ro od du uc ct ti io on nAcute myocardial infarction (MI) is frequently associated with left ventricular (LV) remodeling leading to progressive heart failure (HF). LV remodeling after acute MI is an impor- DOI: 10.4250/jcu.2010.18.3.77 E Ev va al lu ua at ti io on n o of f C Ca ar rd di ia ac c F Fu un nc ct ti io on n b by y T Tr ra an ns st th ho or ra ac ci ic c E Ec ch ho oc ca ar rd di io og gr ra ap ph hy y i in n S Su ub bj je ec ct ts s w wi it th h S ST T--S Se eg gm me en nt t E El le ev va at ti io on n M My yo oc ca ar rd di ia al l I O OR RI IG GI IN NA AL L A AR RT TI IC CL LE EIn nf fa ar rc ct ti io on n F Fo ol ll lo ow wi in ng g P Pr ri im ma ar ry y P Pe er rc cu ut ta an ne eo ou us s C Co or ro on na ar ry y I In nt te er rv ve en nt ti io on n a ac cc co or rd di in ng g t to o V Va al ls sa ar rt ta an n D Do os se e: : T Th he e V Va al ls sa ar rt ta an n O On ne e C Ce en nt te er r T Tr ri ia al l The mean follow-up TTE duration was 24 ± 8 months. Deceleration time (188.6 ± 56.3 msec vs. 221.5 ± 71.3 msec, p = 0.01), E/e' (12.24 ± 5.2 vs. 10.1 ± 4.9, p = 0.002), ejection fraction (52.7 ± 8% vs. 55.2 ± 8.4%, p < 0.01), and wall motion score index (1.45 ± 0.30 vs. 1.33 ± 0.32, p < 0.01) showed significant changes during the follow-up period. Wall motion improvement in injured myocardial segments was more frequently observed in the high-dose valsartan group compared to the low-dose group [18/25 (72%) vs. 24/53 (43.7%), p = 0.03]. There was no significant difference in the changes in cardiac dimensions and function between the low and high dose valsartan group. C Co on nc cl lu us si io on n: : In patients with STEMI who undergoing primary PCI, high-dose valsartan treatment may be more helpful than low-dose in improving wall motion in the injured myocardium.